This presentation reviews the latest evidence-based strategies for identifying, diagnosing and managing non-alcoholic fatty liver disease (NAFLD), now recognized as metabolic dysfunction-associated steatotic liver disease (MASLD). The progressive form of this disease, non-alcoholic steatohepatitis (NASH), is on track to become the leading cause of liver transplantation in the United States. Learn about current guidelines, risk-stratification tools, and emerging therapies, and gain insights to improve early detection and optimize patient outcomes.